非在研机构 |
权益机构- |
最高研发阶段临床3期 |
首次获批日期- |
最高研发阶段(中国)- |
特殊审评孤儿药 (欧盟) |
开始日期2027-02-03 |
申办/合作机构 |
开始日期2026-09-01 |
开始日期2026-08-31 |
申办/合作机构 |
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 关节炎 | 临床3期 | 美国 | 2026-05-14 | |
| 关节炎 | 临床3期 | 日本 | 2026-05-14 | |
| 关节炎 | 临床3期 | 比利时 | 2026-05-14 | |
| 关节炎 | 临床3期 | 加拿大 | 2026-05-14 | |
| 关节炎 | 临床3期 | 法国 | 2026-05-14 | |
| 关节炎 | 临床3期 | 德国 | 2026-05-14 | |
| 关节炎 | 临床3期 | 意大利 | 2026-05-14 | |
| 关节炎 | 临床3期 | 西班牙 | 2026-05-14 | |
| 关节炎 | 临床3期 | 瑞士 | 2026-05-14 | |
| 关节炎 | 临床3期 | 英国 | 2026-05-14 |
| 研究 | 分期 | 人群特征 | 评价人数 | 分组 | 结果 | 评价 | 发布日期 |
|---|
临床1期 | 多发性硬化症 oligoclonal bands | 57 | 艱夢願鹽夢築蓋糧積衊(鹽鹽淵觸淵觸顧餘蓋鹽) = all Gr1- 2) occurred in 12 pts with haRMS (DL1, n=2; DL2, n=10) and 12 with PMS (DL1, n=1; DL2, n=11). 艱網艱窪積簾築膚齋鹽 (蓋製廠襯選憲壓糧積繭 ) 更多 | 积极 | 2026-09-23 | ||
临床1期 | 83 | 鹹築遞範鑰遞繭醖鬱簾(構製鏇醖範糧襯廠廠願) = All inflammatory AEs were brief and reversible (). Cytokine release syndrome occurred in 59.0% pts; most were grade 1 (Gr; Gr1, 48.2%; Gr2, 8.4%; Gr3, 1.2%), resolving in median 3 days. Immune effector cell-associated neurotoxicity syndrome occurred in 12.0% of pts; most were Gr 1 (Gr1, 7.2%; Gr2, 1.2%; Gr3, 3.6%), resolving in median 3 days. Cytopenias occurred in only 53% of patients and no prolonged high-grade cytopenias were observed. 築糧窪選範壓願繭製鑰 (憲膚蓋鏇積齋壓鹽鏇淵 ) | 积极 | 2026-02-04 | |||
临床1期 | 14 | (DL1) | 選齋繭製鏇選齋簾壓膚(觸衊窪膚網鏇衊窪壓壓) = 糧製壓鹽窪鬱廠選獵餘 鹽鹽獵襯夢獵鹹壓蓋築 (選顧艱衊壓鏇夢積積構 ) 更多 | 积极 | 2025-10-24 | ||
临床1期 | 系统性红斑狼疮 CD19 | 26 | BMS-986353 10×10^6 CAR+ T cells | 艱衊醖鏇糧襯範簾襯築(簾衊鏇選蓋觸窪醖製範) = 製築廠鏇醖窪蓋繭壓餘 襯餘糧網夢蓋蓋餘蓋糧 (齋襯蓋淵鹽鹽膚願鹹窪 ) 更多 | 积极 | 2025-10-24 | |
BMS-986353 25×10^6 CAR+ T cells | 艱衊醖鏇糧襯範簾襯築(簾衊鏇選蓋觸窪醖製範) = 艱壓構選繭壓願網製鹹 襯餘糧網夢蓋蓋餘蓋糧 (齋襯蓋淵鹽鹽膚願鹹窪 ) 更多 | ||||||
临床1期 | 13 | 選選餘膚鹹簾襯選鬱壓(願夢鹹夢製糧廠製簾築) = 鹹鬱廠衊艱鏇廠衊製廠 膚積壓淵襯醖鹽餘齋膚 (壓遞齋選簾獵餘獵襯鏇 ) 更多 | 积极 | 2025-10-13 | |||
临床1期 | 多发性硬化症 CD19 | 8 | 醖壓淵襯築壓鑰製積憲(願廠衊簾顧衊餘糧淵窪) = 艱壓製廠餘選齋廠憲繭 醖襯醖鏇簾餘繭積淵範 (築醖鏇製範構餘膚製夢 ) 更多 | 积极 | 2025-09-24 |







